Allergic Rhinitis Changes the Sinus Microbiome

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago

Criteria

Inclusion Criteria:

1. Males and females between 18 and 55 years of age.

2. Two year history of seasonal allergic rhinitis.

3. Positive skin test to grass and/or tree antigen.

Exclusion Criteria:

1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.

2. Pregnant or lactating women.

3. Subjects treated with systemic steroids during the previous 30 days.

4. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.

5. Subjects treated with oral antihistamine/decongestants during the previous seven days.

6. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.

7. Subjects treated with immunotherapy and are escalating their dose.

8. Subjects on chronic anti-asthma medications.

9. Subjects with polyps in the nose or a significantly displaced septum.

10. Upper respiratory infection within 14 days prior to study start.